British innovation is reaching extraordinary new heights after a UK biotechnology company successfully completed a groundbreaking mission aboard the International Space Station, potentially paving the way for cancer patients to receive life-changing treatments in the comfort of their own homes.
In another remarkable demonstration of British scientific ingenuity, BioOrbit has harnessed the unique conditions of space to explore a revolutionary new approach to manufacturing cancer medicines, with the potential to reduce hospital visits, improve patients’ quality of life and dramatically cut treatment costs.
The British start-up has successfully completed a six-week experiment aboard the International Space Station (ISS), producing pharmaceutical protein crystals in microgravity on a scale that UK Research and Innovation (UKRI) says has never previously been achieved in space.
The achievement, announced on Friday (October 23), follows a record-breaking £9.8 million investment in the company, highlighting the growing international confidence in Britain’s space technology and biotechnology sectors.
Founded by scientist Dr Katie King and oncology researcher Dr Leonor Teles, BioOrbit is developing technology that could eventually enable certain cancer medicines, currently administered intravenously in hospitals, to be reformulated into injections patients could administer themselves at home.
For people undergoing cancer treatment, particularly those with weakened immune systems or living considerable distances from specialist hospitals, such a development could make an enormous difference.
The company’s pioneering Baby BOX-E pharmaceutical research platform was launched aboard a SpaceX mission from NASA’s Kennedy Space Center in Florida in May this year.
Once aboard the ISS, the equipment used the station’s microgravity environment to produce highly concentrated protein crystals that are difficult to manufacture under normal conditions on Earth.
Gravity can interfere with the formation of delicate protein crystals, affecting their structure and uniformity. In the near-weightless conditions of space, however, scientists can potentially create more consistent crystalline structures, opening up new possibilities for developing and delivering complex medicines.
BioOrbit believes the process could allow certain antibody-based cancer therapies to be manufactured in more concentrated and stable forms, making them suitable for injection beneath the skin rather than lengthy intravenous infusions.
The company estimates that the approach could eventually reduce drug administration costs by as much as 90 per cent, although this remains a projection rather than a demonstrated saving.
Crucially, the technology is still being developed. The successful space mission does not mean that cancer medicines manufactured using the process are ready for patients. Further development, clinical testing and regulatory approval would be required before treatments could become available.
Nevertheless, the achievement represents an important milestone in a rapidly developing field of pharmaceutical research.
BioOrbit’s success is also a testament to the strength of Britain’s scientific and entrepreneurial infrastructure.
The company has received support through the European Space Agency Business Incubation Centre United Kingdom (ESA BIC UK), part of the Science and Technology Facilities Council’s DeepTech Catalyst programme.
Working in partnership with the European Space Agency, the UK Space Agency and the University of Leicester, the programme helps ambitious British businesses turn cutting-edge space research into commercially viable technologies.
Since joining the initiative in 2023, BioOrbit has developed the specialist equipment needed to conduct pharmaceutical manufacturing experiments in orbit, culminating in its first successful ISS mission.
The company has also secured £9.8 million in seed funding, announced in April, in an investment round jointly led by venture capital firms LocalGlobe and Breega, with additional backing from Auxxo, Seedcamp, Type One, 7percent and private investors.
According to the BioIndustry Association, the investment represented the largest seed funding round secured by a business specialising in pharmaceutical manufacturing in space.
BioOrbit has also benefited from UK Space Agency support, including a £250,000 feasibility study examining scalable in-orbit manufacturing and the regulatory requirements associated with producing medicines beyond Earth.
Dr Katie King, BioOrbit’s founder and chief executive, said the latest mission represented an important step towards transforming the way patients receive treatment.
“This mission marks the beginning of a new era in how medicines can be manufactured,” she said.
“By manufacturing therapies in microgravity, we can unlock formulations that have the potential to make cancer treatment more accessible, more effective and far easier for patients to receive.”
She added: “Our vision is simple: to help move cancer treatment from the hospital ward to the home.”
The company’s ambitions extend considerably further than a single experiment.
Over the next decade, BioOrbit hopes to establish a pharmaceutical manufacturing facility in space, producing specialised medicines that could then be returned to Earth for use by patients.
Such a development would represent a significant expansion of the commercial space economy, transforming orbital infrastructure from a centre of scientific experimentation into a potential manufacturing base for some of the world’s most advanced medicines.
The wider achievements of the British space technology incubation programme are equally impressive.
An independent evaluation published to coincide with ESA BIC UK’s 15th anniversary found that the initiative has supported 179 start-ups across the country since its establishment in 2011.
Those businesses have helped create and sustain more than 1,060 jobs and raised approximately £340 million in private investment.
The evaluation also found that every £1 invested in the programme had generated an estimated £11 in additional economic benefit.
It is evidence of how investment in research, engineering and entrepreneurial talent can support British businesses, create skilled employment and help the country compete in emerging global industries.
Paul Vernon, Executive Director for Business and Innovation at the Science and Technology Facilities Council, welcomed BioOrbit’s achievement.
“BioOrbit represents exactly the kind of bold, potentially world-changing innovation the ESA BIC UK was created to support,” he said.
“By applying the unique environment of space to one of healthcare’s biggest challenges, the company is opening up exciting new possibilities for how complex cancer medicines could be manufactured and delivered.”
He added that, if successful, the technology could help cancer patients receive less invasive treatment at home.
British astronaut Major Tim Peake has also previously praised BioOrbit’s work, describing its approach as an example of using advances in space technology to improve life on Earth.
While considerable scientific and regulatory challenges remain before space-manufactured cancer medicines become a routine part of healthcare, the progress already achieved demonstrates the extraordinary potential of British innovation.
From pioneering research laboratories and specialist engineering companies to ambitious young entrepreneurs prepared to push the boundaries of what is possible, Britain continues to make its mark in some of the world’s most advanced scientific fields.
And if BioOrbit’s vision becomes reality, one of the most important benefits of Britain’s growing presence in space may ultimately be felt not hundreds of miles above Earth, but in the homes of cancer patients here in Britain and around the world.
